Portugal BioTech Showcase @ JPM week
Event Information
Description
Join us to overlook the Portuguese Biotech scene, to connect with Luso-American entrepreneurs and scientists in the Bay Area and to get to know how Portugal and US are working together in this industry and to learn about Portugal’s ecosystem, strategic partnerships opportunities, the highly educated and English-speaking talent pool, world-class research institutes, attractive immigration policy and government support.
Finally, you will have the chance to meet and hear from some of the hottest Portuguese BioTech startups in the moment.
Agenda:
3:00-3:15pm - Registration
3:15-3:35pm - Welcome & Portugal BioTech scene and Business opportunities
- Teresa Fernandes - Portuguese Trade and Investment Commissioner to the Western USA
- David Braga Malta - Venture Partner at Vesalius Biocapital and Board Member at Portugal's Biotechnology Industry Organization
3:35-4:00pm - Keynote: Portugal-US: A partnership to grow
- John Melo – CEO at Amyris
4:00-4:20pm - Portuguese BioTech Startups Showcase
- CellmAbs
- BSIM Therapeutics
4:20-5:30pm - Networking
Complimentary appetizers and soft drinks will be served.
We thank our main supporters:
Description of the Portuguese Startups:
CellmAbs is a Portuguese biopharmaceutical company, spin-off from NOVA University of Lisbon, focused on the development of the new generation of glyco-immuno-oncology products and personalized therapies for Oncology. These immunotherapies have the potential to slow tumor growth and elicit an immune response from the patients themselves, with an unprecedented degree of affinity and specificity. CellmAbs has raised a seed stage investment of 1.6M USD in Portugal from Hovione Capital and Portugal Ventures.
BSIM Therapeutics is a biotech company focused on the design of organ-targeted, high-quality drug candidates for the treatment of transthyretin-mediated amyloidoses (ATTR), in particular, hereditary transthyretin amyloidosis with polyneuropathy (hATTR‑PN), a life-threatening neurodegenerative pathology affecting adults with sensory-motor impairment and multiple organ failure.BSIM has raised approx. 3M USD and developed novel drug candidates that target the causative agent of hATTR‑PN in the blood plasma and also in the cerebrospinal fluid (CSF).
